2 hours Ago By Defense World Staff
Gilead Sciences ( NASDAQ:GILD – Get Free Report ) ‘s stock had its “sector perform” rating reiterated by investment analysts at Royal Bank of Canada in a report issued on Monday, Benzinga reports. They currently have a $84.00 price objective on the biopharmaceutical company’s stock.
Royal Bank of Canada’s price objective points to a potential downside of 14.28% from the stock’s current price. GILD has been the topic of a number of other research reports.
The Goldman Sachs Group increased their target price on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th.
Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Piper Sandler lifted their price objective on shares of Gilead Sciences from $95.
00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $74.
00 to $96.00 in a research report on Monday, October 21st. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company.
According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $98.39.
Get Our Latest Analysis on Gilead Sciences Gilead Sciences Stock Down 0.4 % Gilead Sciences ( NASDAQ:GILD – Get Free Report ) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.
02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44.
Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%.
The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion.
During the same period in the prior year, the firm earned $2.29 earnings per share. The company’s revenue was up 7.
0% on a year-over-year basis. As a group, research analysts anticipate that Gilead Sciences will post 4.34 EPS for the current year.
Insider Buying and Selling In related news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.
22, for a total value of $13,822,739.60. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $12,626,253.
06. The trade was a 52.26 % decrease in their ownership of the stock.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website . Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.
39, for a total transaction of $620,355.32. Following the sale, the director now directly owns 8,920 shares of the company’s stock, valued at $815,198.
80. This represents a 43.21 % decrease in their position.
The disclosure for this sale can be found here . Insiders have sold a total of 572,824 shares of company stock worth $53,611,715 in the last ninety days. Company insiders own 0.
29% of the company’s stock. Institutional Trading of Gilead Sciences A number of institutional investors have recently bought and sold shares of the company. Bellevue Group AG lifted its stake in shares of Gilead Sciences by 18.
2% in the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after purchasing an additional 7,093 shares during the period. Quantinno Capital Management LP boosted its holdings in shares of Gilead Sciences by 149.
5% during the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after buying an additional 48,910 shares in the last quarter. McAdam LLC grew its position in shares of Gilead Sciences by 16.
7% during the 4th quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock worth $2,344,000 after buying an additional 3,627 shares during the period. IRON Financial LLC acquired a new position in shares of Gilead Sciences during the third quarter valued at about $830,000.
Finally, Capital Investment Advisors LLC raised its stake in Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock worth $35,793,000 after buying an additional 9,791 shares during the period.
Institutional investors own 83.67% of the company’s stock. About Gilead Sciences ( Get Free Report ) Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. Featured Stories Five stocks we like better than Gilead Sciences Health Care Stocks Explained: Why You Might Want to Invest Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential Want to Profit on the Downtrend? Downtrends, Explained. Goldman Sachs vs.
Morgan Stanley—Which Stock Has More Upside? Compound Interest and Why It Matters When Investing 3 Reasons Bulls Will Win on Super Micro Computer Stock Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter ..
